Menu Search
Equities

HUTCHMED (China) Ltd

13:HKG

HUTCHMED (China) Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)27.50
  • Today's Change-0.40 / -1.43%
  • Shares traded1.25m
  • 1 Year change-4.35%
  • Beta1.2630
Data delayed at least 15 minutes, as of Nov 22 2024 03:48 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year HUTCHMED (China) Ltd grew revenues 96.52% from 426.41m to 838.00m while net income improved from a loss of 360.84m to a gain of 100.78m.
Gross margin41.67%
Net profit margin-6.91%
Operating margin-19.78%
Return on assets-3.30%
Return on equity-5.51%
Return on investment-4.65%
More ▼

Cash flow in USDView more

In 2023, cash reserves at HUTCHMED (China) Ltd fell by 29.69m. However, the company earned 219.26m from its operations for a Cash Flow Margin of 26.16%. In addition the company generated 48.66m cash from financing while 291.14m was spent on investing.
Cash flow per share-0.2848
Price/Cash flow per share--
Book value per share6.61
Tangible book value per share6.61
More ▼

Balance sheet in USDView more

HUTCHMED (China) Ltd has a Debt to Total Capital ratio of 9.84%, a higher figure than the previous year's 5.13%.
Current ratio2.81
Quick ratio2.68
Total debt/total equity0.1109
Total debt/total capital0.0984
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.